Skip to content
Clinical Trials
Disease Area
Trial Name
Main Conclusions
Page Link
Bev in primary treatment of ovarian cancer
GOG 218
Use of bevacizumab during and up to 10 months after carboplatin and paclitaxel prolongs PFS by about 4 months in advanced EOC
26. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–2483.
Bev in primary treatment of ovarian cancer
Bevacizumab added to primary chemotherapy, and continued for 12 maintenance cycles, shows improvement in PFS, with OS improvement only in the high risk group.
19. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–2496. Erratum in: N Engl J Med. 2012;366(3):284.
Bev in primary treatment of ovarian cancer
ICON-7 Final Results
BEV added to platinum-based chemo did not increase OS in the studied group as a whole. However, in the subgroup of poor prognosis patients, survival benefit recorded (concordant with PFS results from ICON 7 and GOG 218)
Oza AM, et al, standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Lancet Oncol. 2015; 16: 928-936
Cervical Cancer
Progression-free and overall survival were significantly longer with pembrolizumab than with placebo among patients with persistent, recurrent, or metastatic cervical cancer who were also receiving chemotherapy with or without bevacizumab.
Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856-1867. doi:
There are no rows in this table

Want to print your doc?
This is not the way.
Try clicking the ⋯ next to your doc name or using a keyboard shortcut (
) instead.